Insights
-
10 December, 2024 Regulatory Affairs Articles
Rx to OTC Switch – The ‘Must-Haves’ For Success
-
30 November, 2024 Pharmacovigilance Articles
Risk Based Approach to Auditing in Pharmacovigilance
-
11 November, 2024 Pharmacovigilance
Pharmacovigilance in Switzerland: Navigating Unique Regulatory Challenges
-
30 October, 2024 Regulatory Affairs Articles
Marketing Authorization Transfer Considerations
-
23 October, 2024 Pharmacovigilance Articles
Requirements for Nomination of a PV Contact Person
-
17 October, 2024 Regulatory Affairs Articles
Common Variation Application Invalidation Reasons
-
23 September, 2024 Pharmacovigilance Articles
Breaking Stereotypes of Local Literature Review
-
05 September, 2024 Pharmacovigilance Regulatory Affairs Company news
Insuvia’s New Look and Enhanced Website
-
03 July, 2024 Pharmacovigilance Articles
Local Pharmacovigilance Specifics in the UK: Key Points for Compliance
-
01 July, 2024 Pharmacovigilance Webinars
Webinar on Demand: Implementation of Educational Materials on a National Level in EU
-
20 June, 2024 Pharmacovigilance Regulatory Affairs Company news
Insuvia Co-funded by European Uninion
-
30 May, 2024 Pharmacovigilance Articles
Implementation of Educational Materials on the National Level
-
27 May, 2024 Regulatory Affairs Webinars
Webinar: Mastering Grace Period in EU
-
23 May, 2024 Regulatory Affairs Articles
Grace Period requirements in EU/ EEA
-
14 May, 2024 Regulatory Affairs Articles
Comparison of the CEP and ASMF Procedures
-
22 April, 2024 Regulatory Affairs Articles
Regulatory Insights: Navigating ASMF and CEP Procedures
-
20 April, 2024 Regulatory Affairs Articles
Nitrosamines – what you need to know and consider for new Marketing Authorisation Applications
-
17 April, 2024 Pharmacovigilance Articles
ISO IDMP standards implementation. What should MAHs prepare for?
-
08 March, 2024 Pharmacovigilance Articles
ISO IDMP: EMA‘s Recommendations for Data Migration
-
05 March, 2024 Pharmacovigilance Regulatory Affairs Company news
Insuvia Ranked as the #282 Europe’s Fastest-Growing Company
-
21 February, 2024 Regulatory Affairs Articles
Navigating Labelling Exemptions: Strategies for Market Access (Part II)
-
01 February, 2024 Regulatory Affairs Articles
Navigating Labelling Exemptions: Strategies for Market Access (Part I)
-
07 January, 2024 Pharmacovigilance Articles
Achieving Success in National Scientific Advice Procedures
-
30 November, 2023 Regulatory Affairs Articles
Agreements with Healthcare Professionals – Compliance Considerations
-
23 August, 2023 Regulatory Affairs Articles
Managing Supply Issues with Labelling Exemptions and Foreign Language Packs at National Level in EU/EEA
-
10 July, 2023 Pharmacovigilance Articles
Pharmacovigilance System Set-Up
-
06 June, 2023 Regulatory Affairs Articles
e-PI: Electronic Product Information
-
11 May, 2023 Regulatory Affairs Articles
ISO IDMP: Current Status and Future Developments
-
16 March, 2023 Regulatory Affairs Articles
Building a Culture of Quality and Safety: Deviation and CAPA Management
-
08 March, 2023 Pharmacovigilance Regulatory Affairs Company news
Financial Times names Insuvia as One of Europe’s Fastest Growing Companies
-
09 January, 2023 Regulatory Affairs Articles
EU Clinical Trial Information System (CTIS): Changes In Safety Reporting Requirements
-
28 October, 2022 Pharmacovigilance Articles
LPPV Requirements in EAEU and the Rest of CIS Countries
-
20 September, 2022 Pharmacovigilance Regulatory Affairs Articles
Educational Materials: Review of National Regulatory Requirements in the EU/EEA
-
12 August, 2022 Pharmacovigilance Regulatory Affairs Articles
Pharmaceutical marketing. How to ensure compliance?
-
13 July, 2022 Pharmacovigilance Regulatory Affairs Articles
PV Regulatory Intelligence and its Growing Importance
-
08 June, 2022 Pharmacovigilance Regulatory Affairs Articles
Product Launch in the EU: Regulatory Affairs Considerations
-
06 June, 2022 Company news
Insuvia Becomes ISO 9001:2015 Certified
-
11 May, 2022 Pharmacovigilance Articles
Managing Pharmacovigilance Data Migration
-
22 April, 2022 Pharmacovigilance Articles
Difference Between Vaccinovigilance & Pharmacovigilance
-
19 April, 2022 Pharmacovigilance Articles
Centralizing Safety Data Management
-
04 November, 2021 Regulatory Affairs Articles
Regulatory Affairs Outsourcing Considerations
-
18 October, 2021 Pharmacovigilance Articles
QPPV Outsourcing in EU/EEA and its benefits for MAH
-
21 July, 2021 Pharmacovigilance Articles
Integration of Client-Vendor Pharmacovigilance Systems
-
05 May, 2021 Pharmacovigilance Articles
The Local Safety Responsible (LSR) role in the Arab GVP
-
26 April, 2021 Pharmacovigilance Articles
Clinical Safety Management Plan and its Importance
-
16 December, 2020 Pharmacovigilance Articles
BREXIT – Key Changes in the UK Pharmacovigilance System
-
09 December, 2020 Company news
Insuvia is Opening an Office in London
-
19 October, 2020 Pharmacovigilance Articles
Safety Data Exchange Agreement (SDEA)
-
09 September, 2020 Pharmacovigilance Regulatory Affairs Company news
Insuvia Opens a New Office in Baku, Azerbaijan
-
03 August, 2020 Regulatory Affairs Articles
Bringing the Dossiers into Compliance in the EAEU
-
03 August, 2020 Pharmacovigilance Articles
Periodic Safety Update Report (PSUR) – an Overview
-
22 April, 2020 Pharmacovigilance Articles
Local Person for PV (LPPV) Strategy Considerations
-
02 August, 2019 Pharmacovigilance Regulatory Affairs Company news
“Insuvia” UAB European Union Funded Project